KRAS and pancreatic intraductal papillary-mucinous neoplasm: A meta-analysis of KRAS mutations in pancreatic cystic fluid for diagnosing HGD or IPMN-driven adenocarcinoma showed a sensitivity of 54%, a specificity of 51%, and an AUC of 0.51.